Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alectinib-based biomarker-selected study in resectable ALK-positive NSCLC
ChiCTR2400090972Phase 2Not yet recruiting
- Sponsor
- Guangdong Provincial People's Hospital
- Start
- Oct 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of alectinib in non-small cell lung cancer (NSCLC) (2 cohorts), sponsored by Guangdong Provincial People's Hospital. Primary endpoints: Investigator-assessed pathological complete response and Incidence, type, and severity of adverse events. Planned start Oct 2024; status: not yet recruiting.
02
Drugs
alectinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR2400090972.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400090972.